DV
Dividend Vision

DNA — Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings (DNA)

Total return is -98.3% over the past 5.3 years, 199.0 points behind SPY at 100.7%. Its deepest 1-year drawdown was 66.0%.

This is a single-stock equity position in Ginkgo Bioworks Holdings, a synthetic biology company, rather than a diversified ETF. The holding does not currently pay dividends, resulting in no distribution rate or yield profile. With no expense ratio data available and inception dating to April 2021, this product is primarily suited for investors seeking direct exposure to the company's biotech operations rather than income-focused dividend investors.

DNA key facts

Asset type
Stock
Asset class
Equity
Inception date
04/19/2021
Last close
$6.79
Market cap
$516,716,736
Average volume
1448000.0
Beta
1.778
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.38